Passa ai contenuti principali

COVID vaccine revelation sinks like a stone; disappears



In major media, certain stories gain traction. The trumpets keep blaring for a time before they fade.

Other stories are one-offs. A few of them strike hard. Their implications—if anyone stops to think about them—are powerful. Then…nothing.

"Wait, aren't you going to follow up on that? Don't you see what that MEANS?"

Apparently not, because…dead silence. "In other news, the governor lost his pet parakeet for an hour. His chief of staff found it taking a nap in a desk drawer…"

One-offs function like teasers. You definitely want to know more, but you never get more.

Over the years, I've tried to follow up on a few. The reporter or the editor has a set of standard replies: "We didn't get much feedback." "We covered it." "It's now old news." "There wasn't anything else to find out."

Oh, but there WAS.

A few weeks ago, I ran a one-off. The analysis and commentary were mine, but the story was an opinion piece in the New York Times. The Times called it an opinion piece to soften its blow. I suspected it would disappear, and it did.

Its meaning and implication were too strong. It would be a vast embarrassment for the White House, the Warp Speed COVID vaccine program, the vaccine manufacturers, the coronavirus task force, and vaccine researchers.

And embarrassment would be just the beginning of their problem.

So…here it is again. The vanished one-off, back in business:

COVID vaccine clinical trials doomed to fail; fatal design flaw; NY Times opinion piece exposes all three major clinical trials. [2]

Peter Doshi, associate editor of the medical journal BMJ, and Eric Topol, Scripps Research professor of molecular medicine, have written a devastating NY Times opinion piece about the ongoing COVID vaccine clinical trials.

They expose the fatal flaw in the large Pfizer, AstraZeneca, and Moderna trials.

September 22, the Times: "These Coronavirus Trials Don't Answer the One Question We Need to Know" [1]:

"If you were to approve a coronavirus vaccine, would you approve one that you only knew protected people only from the most mild form of Covid-19, or one that would prevent its serious complications?"

"The answer is obvious. You would want to protect against the worst cases."

"But that's not how the companies testing three of the leading coronavirus vaccine candidates, Moderna, Pfizer and AstraZeneca, whose U.S. trial is on hold, are approaching the problem."

"According to the protocols for their studies, which they released late last week, a vaccine could meet the companies' benchmark for success if it lowered the risk of mild Covid-19, but was never shown to reduce moderate or severe forms of the disease, or the risk of hospitalization, admissions to the intensive care unit or death."

"To say a vaccine works should mean that most people no longer run the risk of getting seriously sick. That's not what these trials will determine."

This means these clinical trials are dead in the water.

The trials are designed to show effectiveness in preventing mild cases of COVID, which nobody should care about, because mild cases naturally run their course and cause no harm. THERE IS NO NEED FOR A VACCINE THAT PREVENTS MILD CASES.

There. That's the NY Times one-off. My piece analyzing it went on much longer, but you get the main thrust:

The leading vaccine clinical trials are useless, irrelevant, misleading, and deceptive.

But now, it gets much worse. Because Pfizer has just announced their vaccine is almost ready. CNBC headline, November 9: "Pfizer, BioNTech say Covid vaccine is more than 90% effective—'great day for science and humanity'" [3].

And not a peep about the NY Times one-off. That's gone, as if it never was.

Trump's coronavirus task force knows the truth. Biden's new task force, waiting in the wings, knows the truth. But they don't care. They're criminals. They'd sell a car with a gas tank ready to explode to a customer with cash.

But you care, because you can read and think.

You can raise hell.

Now, in case anyone is interested in knowing WHY the major clinical trials of the COVID vaccine are designed only to prevent mild cases of COVID, I'll explain.

A vaccine maker assumes that, during the course of the clinical trial, a few of the 30,000 volunteers are going to "catch COVID-19."

They assume this because "the virus is everywhere," as far as they're concerned. So it'll drop down from the clouds and infect a few of the volunteers.

The magic number is 150. When that number of volunteers "catch COVID," everything stops. The clinical trial stops.

At this point, the vaccine maker hopes that most of the volunteers who "got infected" are in the placebo group. They didn't receive the real vaccine; they received the saltwater placebo shot.

Then the vaccine maker can proudly say, "See? The volunteers who caught COVID-19? Most of them didn't receive the vaccine. They weren't protected. The volunteers who received the real vaccine didn't catch COVID. The vaccine protected them."

Actually, the number split the vaccine makers are looking for is 50 and 100. If 50 people in the vaccine group catch COVID, and 100 in the placebo group catch COVID, the vaccine is said to be 50% effective. And that's all the vaccine maker needs to win FDA approval for the vaccine.

But wait. Let's look closer at this idea of "catching COVID." What are they really talking about? How do they define that? Claiming a volunteer in the clinical trial caught COVID adds up to what?

Does it add up to a minimal definition of COVID-19—a cough, or chills and fever? Or does it mean a serious case—severe pneumonia?

Now we come to the hidden factor, the secret, the source of the whole con game.

You see, the vaccine maker starts out with 30,000 HEALTHY volunteers. So, if they waited for 150 of them to come down with severe pneumonia, a serious case of COVID, how long do you think that would take? Five years? Ten years?

The vaccine maker can't possibly wait that long.

These 150 COVID cases the vaccine maker is looking for would be mild. Just a cough. Or chills and fever. That scenario would only take a few months to develop. And face it, chills, cough, and fever aren't unique to COVID. Anyone can come down with those symptoms.

THEREFORE, THE WHOLE CLINICAL TRIAL IS DESIGNED, UP FRONT, TO FIND 150 CASES OF MILD AND MEANINGLESS AND SELF-CURING "COVID."

About which, no one cares. No one should care.

But, as we see, Pfizer is trumpeting their clinical trial of the vaccine as a landmark in human history.

And THAT'S the story of the one-off the NY Times didn't think was worth a second glance.

Because they're so stupid? No. They're not that stupid.

They're criminals.

And the government wants you to take the experimental COVID vaccine, whose "effectiveness" was designed to prevent nothing worth losing a night's sleep over.

The only worry are the adverse effects of the vaccine, about which I've written extensively. These effects include, depending on what's in the vial, a permanent alteration of your genetic makeup, or an auto-immune cascade, in which the body attacks itself.


SOURCES:

[1] nytimes.com/2020/09/22/opinion/covid-vaccine-coronavirus.html

[2] https://blog.nomorefakenews.com/2020/09/24/covid-vaccine-clinical-trials-doomed-to-fail-fatal-design-flaw/

[3] https://www.cnbc.com/2020/11/09/covid-vaccine-pfizer-drug-is-more-than-90percent-effective-in-preventing-infection.html

L



Fabrizio 

Commenti

Post popolari in questo blog

Fwd: The Looming Bank Collapse The U.S. financial system could be on the cusp of calamity. This time, we might not be able to save it.

After months  of living with the coronavirus pandemic, American citizens are well aware of the toll it has taken on the economy: broken supply chains, record unemployment, failing small businesses. All of these factors are serious and could mire the United States in a deep, prolonged recession. But there's another threat to the economy, too. It lurks on the balance sheets of the big banks, and it could be cataclysmic. Imagine if, in addition to all the uncertainty surrounding the pandemic, you woke up one morning to find that the financial sector had collapsed. You may think that such a crisis is unlikely, with memories of the 2008 crash still so fresh. But banks learned few lessons from that calamity, and new laws intended to keep them from taking on too much risk have failed to do so. As a result, we could be on the precipice of another crash, one different from 2008 less in kind than in degree. This one could be worse. John Lawrence: Inside the 2008 financial crash The financial

3 Reasons Why Gold Will Outperform Equities And Bonds

3 Reasons Why Gold Will Outperform Equities And Bonds https://www.forbes.com/ 3 Reasons Why Gold Will Outperform Equities And Bonds For centuries, gold has played a major role in human history and has become interwoven into the financial fabric of society. Beyond its investment following, gold has become synonymous with wealth. Historically, gold's early use cases revolved around money – a form of "medium of exchange". After the second world war however, several countries and their respective currencies, started to shift away from the gold standard and migrated towards a fiat currency system. Today, gold remains largely a "Store of Value", and due to its unique properties and large number of use cases, it has managed to distance itself from other asset classes in terms of correlation, demand / supply drivers, and investment purpose. Gold's idiosyncrasies function as a double-edged sword, as it is challenging to predict

What Will Stocks Do When “Consensual Hallucination” Ends?

The phenomenon works – until it doesn't. What's astonishing is how long it works. There is a phenomenon in stock markets, in bond markets, in housing markets, in cryptocurrency markets, and in other markets where people attempt to get rich. It's when everyone is pulling in the same direction, energetically hyping everything, willfully swallowing any propaganda or outright falsehood, and not just nibbling on it, but swallowing it hook, line, and sinker, and strenuously avoiding exposure to any fundamental reality. For only one reason: to make more money. People do it because it works. Trading algos are written to replicate it, because it works. It works on the simple principle: If everyone believes stocks will go up, no matter what the current price or the current situation, or current fundamental data, then stocks will go up. They will go up because there is a lot of buying pressure because everyone believes that everyone believes that prices will go up, and so they bid up